Policy record · research context · current through April 2026

Regulatory Timeline

A practical record of the agency decisions, state actions, international controls, and research milestones shaping ibogaine and noribogaine clinical development.

This page separates trial authorizations, formal approvals, policy endorsements, and funding announcements. Those categories can have very different legal and practical meanings.

Earth-toned research materials arranged for a regulatory timeline review

Foundations

From controlled substance status to investigational research

Ibogaine’s regulatory history begins with a distinction that remains important: a controlled substance can still be studied under federal research rules, but that status does not create a pathway for ordinary clinical use.

1967

United States schedules ibogaine

Ibogaine was placed in Schedule I under U.S. federal controlled-substance law. The DEA’s controlled-substances schedule continues to list ibogaine in Schedule I, a category that places substantial controls around manufacturing, handling, storage, and research registration.

What this means: Schedule I status is not a determination that research cannot occur. It means research is subject to specific federal controls and institutional requirements.

1970s–1990s

International control and a research record develop in parallel

Countries have taken different approaches to ibogaine and iboga-containing plants, while scientific discussion has continued across pharmacology, toxicology, and dependence research. The historical overview of ibogaine is useful for orientation, but legal status must always be checked against current law in the relevant jurisdiction.

What this means: International policy is not one rulebook. A development program must account for the jurisdictions where a substance is made, studied, shipped, and ultimately reviewed.

2000s–2010s

Safety questions become inseparable from policy questions

Cardiac safety concerns, including QT-interval prolongation, became central to how investigators and regulators approached ibogaine. The FDA guidance on QT/QTc assessment describes the broader regulatory framework used to evaluate proarrhythmic potential for non-antiarrhythmic drugs.

What this means: Evidence plans for ibogaine-related compounds need to address monitoring, screening, dosing, product quality, and protocol safeguards rather than treating safety as a separate afterthought.

The maker’s bench

Development language needs careful labels

An investigational new drug authorization, a state research initiative, a policy resolution, and a marketing approval are not interchangeable. Keeping those labels intact helps readers evaluate pipeline announcements without turning preliminary work into a clinical claim.

For current study records, the trial tracker’s study-by-study view can be read alongside the safety and risk context, particularly where trial eligibility and monitoring procedures are concerned.

“Authorization to investigate is a permission to gather evidence under a defined protocol—not a conclusion about treatment outcomes.”

Research notes and natural materials representing careful evidence review

Federal and state actions

A changing policy environment, not a blanket authorization

Recent U.S. actions have increased attention to psychedelic research and drug-development pathways. Their scope remains defined by the text of each order, statute, grant, or agency decision.

2023–2025

State policy initiatives create research-facing pathways

Several states considered or enacted measures that fund, study, or establish processes around psychedelic research. These actions can direct state agencies, commission evidence reviews, or support research infrastructure; they do not by themselves reschedule ibogaine federally or establish a federal approval pathway.

Readers looking at the treatment-policy discussion can compare these developments with ibogaine and ALS research context, while keeping disease-focused investigation distinct from an approved indication.

What this means: State-level momentum may affect research capacity and policy debate, but the legal effect depends on the particular measure and subsequent implementation.

2025

Federal executive direction elevates the broader drug-development discussion

Executive actions concerning access to emerging therapies and the modernization of regulatory processes can set agency priorities, request reports, or encourage coordination. They are policy direction, not drug approval decisions. The White House record of presidential actions provides the primary-document context for reviewing an executive order’s actual language and limits.

What this means: An executive order can influence the environment around research and review, but FDA standards for safety, effectiveness, manufacturing, and labeling remain separate statutory processes.

2025–2026

Research funding and pipeline announcements require separate reading

Funding awards, company pipeline updates, and pilot programs can signal that a program is moving forward, but they are not agency findings. For a useful distinction between exploratory activity and formal studies, see the discussion of ibogaine pilot programs and the background on how ibogaine is defined in practice.

What this means: A funding announcement can support future work without establishing that a product has met any clinical or regulatory standard.

April 2026 checkpoint

Noribogaine receives an FDA trial authorization

The April 2026 FDA authorization for a noribogaine clinical investigation is a consequential regulatory event, but it should be understood at the level it was granted: authorization to conduct a defined investigational study.

What occurred

Study authorization

The authorization permits the sponsor to proceed with the specified clinical protocol under FDA oversight. It concerns noribogaine, an ibogaine-related compound, and the particular investigational plan submitted to the agency.

What did not occur

No marketing approval

The action is not FDA approval for routine prescribing or commercial marketing. It does not establish an approved indication, a standard dose, or a conclusion about clinical benefit.

Why the distinction matters

Evidence remains to be generated

Trial authorization allows evidence to be collected using planned safeguards and endpoints. Later regulatory decisions, if any, depend on the data and the applicable review standards.

Reading the record

Context for the pipeline

Questions about compound form and timing can be important when interpreting study design. The practical reference on ibogaine hydrochloride context and the explanation of reported ibogaine duration are useful background, but neither changes the legal meaning of a trial authorization.

Working definitions

Questions that keep the timeline honest

Regulatory milestones are easiest to interpret when their scope is kept visible. For broader research-development framing, the independent ibogaine research resource gathers related context without presenting investigational work as established care.

Does an FDA trial authorization mean ibogaine or noribogaine is approved?

No. An authorization to study an investigational product permits a defined clinical investigation under a protocol. It is not a marketing approval, a finding of efficacy, or an authorization for routine clinical use.

How should state policy announcements be read?

State actions can support research, create study pathways, or direct agencies to examine policy options. Their legal effect depends on the text, implementing rules, and the scope of the action; they do not automatically change federal scheduling or establish a treatment standard.

Why does safety remain central to regulatory discussion?

Ibogaine has documented cardiac risk considerations, including QT-interval effects. Regulatory review therefore depends on protocol design, screening, monitoring, product quality, and the evidence generated in formal studies. The context for supervised ibogaine settings is not a substitute for individual medical assessment or for the safeguards in a registered clinical protocol.

Keep the categories clear

Follow the record, not the hype.

Regulatory language can be technical, but its distinctions matter: investigational research, policy support, funding, and product approval each describe a different stage and carry different implications.

Our evidence approach